Salarius Pharmaceuticals Notified By MD Anderson Cancer Center Of Grade 4 Adverse Event In Seclidemstat Clinical Trial; FDA Places Trial On Partial Clinical Hold; No New Patients Enrolled, Current Patients May Continue Treatment; Company To Support...
Salarius Pharmaceuticals Notified By MD Anderson Cancer Center Of Grade 4 Adverse Event In Seclidemstat Clinical Trial; FDA Places Trial On Partial Clinical Hold; No New Patients Enrolled, Current Patients May Continue Treatment; Company To Support...
Salarius pharmaceuticals向MD Anderson癌症中心通報，Seclidemstat臨床試驗中發生4級不良事件；FDA將試驗部分暫停；不招募新病人，當前患者可以繼續治療；公司將支持數據分析，並回應FDA的問題。
Salarius Pharmaceuticals Notified By MD Anderson Cancer Center Of Grade 4 Adverse Event In Seclidemstat Clinical Trial; FDA Places Trial On Partial Clinical Hold; No New Patients Enrolled, Current Patients May Continue Treatment; Company To Support Data Analysis And Respond To FDA Queries
Salarius Pharmaceuticals接到MD Anderson癌症中心關於Seclidemstat臨床試驗的4級不良事件通知；FDA將試驗部分暫停；不招募新患者，目前患者可繼續治療；公司將支持數據分析並回答FDA的問題
- 8K Filing
-0.8萬份申請
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。